|Programs + Specialties
|Training + Education
McGill University Faculty of Medicine, Canada; Cambridge Hospital; University of Michigan Medical Center; Carney Hospital; The Cambridge Hospital
Tufts Medical Center Primary Care
800 Washington St., #235
Boston, MA 02111
Fax #: 617-636-1384
Phone #: 617-636-5400
1984-85 “CRC Award for Excellence in Chemistry”, as top student in Inorganic Chemistry. Also top student in Biochemistry, Physics, and Physical Chemistry, Binghamton University, State University of New York.
1986 “Outstanding Academic Achievement” Award and “James Wilmouth Award” as top graduate in Biology, State University of New York at Binghamton
1990-91 “Faculty Scholar,” McGill University, Faculty of Medicine, (awarded to top 10% of class each year)
1991 “University Scholar,” McGill University, Faculty of Medicine, (awarded to top 10% of graduating class)
1998 “Lee Lusted Award” for best research presentation (Second Prize), Society for Medical Decision Making, National Meeting, Cambridge, MA
1999 “Trainee Award” for best research presentation, Midwest Regional Society for General Internal Medicine Meeting, Chicago, IL
2000 Keynote Address, Tufts University School of Medicine Commencement
2000 Tufts University Faculty Recognition Award
2001-02 Tufts University School of Medicine, Faculty Recognition Award for Excellence in Teaching
2002 Pfizer Scholar in Clinical Epidemiology
2010 Invited Speaker, Princeton Stroke Conference, Boston
1. Kent DM, Ruthazer R, Weimar C, Mas JL, Serena J, Homma S, Di Angelantonio E, DiTullio MR, Lutz JS, Elkind MS, Griffith J, Jaigobin C, Mattle HP, Michel P, Mono ML, Nedeltchev K, Papetti F, Thaler DE. An Index to Identify Stroke-related versus Incidental Patent Foramen Ovale in Cryptogenic Stroke. Neurology 2013;81(7):619-625. PMCID: PMC3775694
2. Kitsios GD, Dahabreh IJ, Abu Dabrh AM, Thaler DE, Kent DM. Patent Foramen Ovale Closure and Medical Treatments for Secondary Stroke Prevention: A Systematic Review of Observational and Randomized Evidence. Stroke 2012;43(2):422-431. PMCID: PMC3342835
3. Dahabreh IJ, Kent DM. Index event bias as an explanation for the paradoxes of recurrence risk research. JAMA 2011;305(8):822-823. PMID: 21343582
4. Kent DM, Rothwell PM, Ioannidis JPA, Altman DG, Hayward RA. Assessing and Reporting Heterogeneity in Treatment Effects in Clinical Trials: A Proposal. Trials 2010;11(1):85. PMCID: PMCID: PMC2928211
5. Kent DM, Hayward RA. Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification. JAMA 2007;298(10):1209-1212. PMID: 17848656
6. Alsheikh-Ali AA, Thaler DE, Kent DM. Patent Foramen Ovale in Cryptogenic Stroke: Incidental or Pathogenic? A Systematic Review and Bayesian Approach. Stroke 2009;40(7):2349-2355. PMCID: PMCID: PMC2764355
7. Trikalinos TA. Alsheikh-Ali AA. Tatsioni A. Nallamothu BK. Kent DM. Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis. Lancet 2009;373(9667):911-8. PMCID: PMC2967219
8. Kent DM, Selker HP, Ruthazer R, Bluhmki E, Hacke W. The stroke--thrombolytic predictive instrument: a predictive instrument for intravenous thrombolysis in acute ischemic stroke. Stroke 2006;37:2957-2962. PMID: 17068305
9. Kent DM, Price LL, Ringleb PA, Hill MD, Selker HP. Sex-based differences in response to rt-PA in acute ischemic stroke: A pooled analysis. Stroke 2005;36(1):62-65. PMID: 15569865
10. Kent DM, Hayward RA, Griffith JL, Vijan S, Beshansky JR, Califf RM, Selker HP. An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase. Am J Med 2002;113:104-111. PMID: 12133748
David M. Kent, MD, MSc is a clinician-methodologist most interested in the problems of making inferences to individual patients based on effects measured in groups. He has a broad background in clinical epidemiology with a focus on predictive modeling in cardiovascular and cerebrovascular disease (CVD), as well as experience in meta-analytic approaches, particularly individual patient data meta-analysis as the basis for risk modeling. He is currently PI of 5 active federally funded research grants related to risk modeling and heterogeneity of treatment effects (HTE), as well as other funded research awards from industry and foundations. In addition to applied work in CVD, this funded work also addresses fundamental analytic issues in how to employ risk-modeling approaches to clinical trial analysis to better anticipate HTE. He is currently PI on a PCORI methods grant empirically evaluating a framework to examine HTE in randomized clinical trials, co-PI (with Issa Dahabreh of Brown Univeristy) on a second PCORI methods grant which makes use of both observational data and data from randomized trials in order to investigate HTE, as well as PI (with Peter Neumann) of a U Award which examines the value of risk-modeling. Finally, he is PI of the NIH-sponsored RoPE and TAcTiCS projects, which examine the role of PFO in cryptogenic stroke, on which he collaborates closely with David Thaler. Dr. Kent’s research efforts have recently been organized in a new center at Tufts, the Tufts Predictive Analytics and Comparative Effectiveness (PACE) Center, which he directs. In addition, a considerable portion of Dr. Kent’s time is spent educating and mentoring future clinical researchers, as Director of the Clinical and Translational Science Program, at the Sackler School of Graduate Biomedical Sciences, and Director of a T-funded Training Program.
Development of the Stroke-TPI is described in the following articles:
Kent DM. Selker HP. Ruthazer R. Bluhmki E. Hacke W. The stroke--thrombolytic predictive instrument: a predictive instrument for intravenous thrombolysis in acute ischemic stroke. Stroke. 37(12):2957-62, 2006 Dec.
Kent DM. Selker HP. Ruthazer R. Bluhmki E. Hacke W. Can multivariable risk-benefit profiling be used to select treatment-favorable patients for thrombolysis in stroke in the 3- to 6-hour time window? Stroke. 37(12):2963-9, 2006 Dec.
Please note that The Stroke-TPI has not been prospectively tested in clinical trials and this web-version is intended for academic not clinical use. The use of thrombolytic therapy in acute stroke should follow current guidelines together with physician judgement; rt-PA is FDA-approved for use in acute ischemic stroke only up to 3-hours from symptom onset.
SOLARIS (Selection Of Lytic Agent for Reperfusion Information System)
SOLARIS is intended to support selection of thrombolytic agent (tPA versus streptokinase) in acute myocardial infarction. Its development and testing is described in:
Kent DM, Hayward RA, Griffith JL, Vijan S, Beshansky JR, Califf RM, Selker HP . An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase. American Journal of Medicine 2002;113:104-11.
Kent DM, Vijan S, Hayward RA, Griffith JL, Beshansky JR, Selker HP. Tissue plasminogen activator was cost-effective compared to streptokinase only in selected patients with acute myocardial infarction. Journal of Clinical Epidemiology 2004;57:843-52.